Valneva licenses EB66 technology to IAVI to develop HIV vaccine
The agreement is the first time Valneva has granted dual rights to a non-profit organization, allowing for both research and clinical studies using its proprietary technology. Valneva previously granted the rights in two separate agreements.
"Our licensing agreement with Valneva gives IAVI access to an exciting technology in vaccine design," IAVI Deputy Director of Design and Development Christopher Parks said. "We look forward to working with Valneva on our CDV candidate as part of a broad pipeline of novel HIV vaccine candidates."
Valneva's EB66 is a cell line technology for the development of human and veterinary vaccines. It has passed a Phase II study and was developed from a similar type of canine distemper virus. IAVI seeks to develop a vaccine to prevent HIV with the technology and fight AIDS worldwide.
"It is of great importance for Valneva that the company contributes to the advancement of vaccines against global health threats," Valneva's President and Chief Executive Officer Thomas Lingelbach and President and Chief Business Officer Franck Grimaud said. "We are very excited to work with a first-class organization like IAVI and we look forward to their progress in advancing this novel HIV vaccine candidate."